SCHEMBL5608007

SCHEMBL5608007

CC(=O)NCc1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.61
▸ PTGS1 P23219 3/20 0.59
▸ ALPI P09923 1/20 0.59
▸ PKM P14618 1/20 0.59
▸ XIAP P98170 1/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ ALOX15 P16050 3/20 0.51
▸ HIF1A Q16665 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ HDAC1 Q13547 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ EGFR P00533 1/20 0.51
▸ LCK P06239 1/20 0.51
▸ FYN P06241 1/20 0.51
▸ ADORA3 P0DMS8 1/20 0.51
▸ HTR2A P28223 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ RECQL P46063 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5608012 1.00 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL16577961 0.84 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL12611747 0.84 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL8423731 0.83 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4629840 0.83 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4629839 0.83 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.83 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL5607268 0.83 HPGD (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL5607271 0.83 HPGD (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL8237191 0.82 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP SLC7A5 2674/4885PTGS1 1654/4885ALPI 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback